WillItSurvive
Retail and consumer conglomerates · China

China Feihe

China's top infant formula maker, pivoting to adult nutrition as births shrink.

Losing its protection
Assessed 26 July 2026 · Evidence as of 26 July 2026
The structural protection is eroding.
On the recordSince 26 July 2026 · Checkable from ~28 August 2026 · Every call on the record Checkpoint: H1 2026 earnings release, watched for revenue stabilization and diversification progress
The call

Feihe still leads China's infant formula market but faces a shrinking birth pool and a domestic rival gaining ground, with its future tied to diversification that has not yet shown up in results.

Feihe makes infant formula and other dairy products in China, where it operates 14 factories and has built a strong local distribution network that foreign companies find hard to break into. However, a domestic rival called Yili has started outselling Feihe in stores, and China's birth rate has dropped sharply, which means fewer babies to feed and smaller profits for the whole industry. The company's fortunes will likely turn on whether it can successfully sell adult nutrition products and premium baby formulas, or expand to nearby countries like Vietnam and Thailand, but those new businesses have not yet made a real dent in the company's earnings.

Why
01
AI pressure: None apparent. AI has no meaningful role in infant formula demand, production, or distribution for Feihe today. Could AI do the core job? Unlikely.
02
Bigger players: Yili. Yili passed Feihe in retail milk-powder share in H1 2025, 18.1% versus Feihe trailing, per market tracking. Could a giant copy it? Probably.
03
What protects it. Chinese regulatory approvals, 14 owned factories, and deep offline distribution keep foreign brands out, though not domestic rivals like Yili.
What would change this call
Next Kantar/Nielsen retail tracking (2026) on Feihe vs Yili infant formula share. Shows whether Yili's share lead over Feihe widens or narrows.
China Feihe H1 2026 earnings (~28 August 2026) revenue and profit figures. Shows whether core infant-formula decline is stabilizing or deepening.
Reported revenue contribution from adult nutrition and Southeast Asia lines in 2026 filings. Shows whether diversification is offsetting core formula losses.
Key numbers
  • FY2025 revenue fell 12.7% to RMB18,112.6 million (2026-03-26)
  • FY2025 net profit dropped 42.7% to RMB2,093.8 million (2026-03-26)
  • China recorded a record-low ~7.92 million births (2025-12-31)
Named risks
  • Core infant formula TAM shrinking as China births hit record low ~7.92M in 2025. Severity: high
  • Domestic rival Yili has overtaken Feihe in retail share as of H1 2025. Severity: high
  • 88% revenue concentration in infant formula with unproven diversification into adult nutrition and Southeast Asia. Severity: medium
  • Operating cash flow fell from RMB4.18B to RMB2.214B in 2025, signaling margin and cash generation pressure. Severity: medium
  • ESG reputational exposure: 0% Policy Commitment score on Access to Nutrition Foundation BMS Index. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Yililosing toYili overtook Feihe in overall retail milk powder share in H1 2025, 18.1% vs Feihe trailing, per 36kr on 2025-10-19
Health and Happiness Group (H&H)losing toH&H infant formula sales grew 28.3% YoY while Feihe revenue fell, per 36kr 2026-05-21
Danonelosing toDanone China nutrition segment grew 13.2% to EUR2.77B in 2025 while Feihe revenue declined, per 36kr 2026-05-21
Mengniu DairycontestingCOFCO backed broader dairy rival competing in adjacent liquid milk category, ongoing as of 2026
Junlebao DairycontestingPrice competitive second tier discounter pressuring Feihe segment, per 36kr 2026-07-13
Questions people ask
Is China Feihe profitable in 2026?
Yes but shrinking. China Feihe posted FY2025 net profit of RMB2,093.8 million, down 42.7% from RMB3,654.1 million in 2024, on revenue of RMB18,112.6 million, down 12.7% year on year, per its annual results announcement dated 2026 03 26.
Is China Feihe losing market share to Yili?
Third party retail tracking cited by 36kr on 2025 10 19 shows Yili overtook Feihe in overall milk powder retail share in H1 2025, with Yili at 18.1% while Feihe trailed, ending Feihe's prior six year leadership in China's infant formula category.
Could AI replace China Feihe's core business?
Unlikely soon. Feihe's moat rests on regulated food safety approvals, 14 vertically integrated factories, and offline distribution and trust networks, none of which AI can replicate. AI is used for marketing and demand forecasting, with a company claimed 92% accuracy figure as of 2026 05 21, not core disruption.
Who owns China Feihe?
China Feihe Limited is publicly listed on the Hong Kong Stock Exchange (6186.HK) since its IPO on 13 November 2019, with minority institutional holders including Norges Bank, BlackRock entities, Dimensional Fund Advisors and Vanguard funds, each holding sub 2% stakes as of 2026 07 08.
Why is China Feihe's stock down so much?
China Feihe's stock fell from a 2021 high of about HK$25.7 to roughly HK$2.8 to 3.9 through 2026, an over 85% decline, reflecting market concern over China's record low 2025 birth rate of about 7.92 million and falling infant formula revenue, per 36kr reporting dated 2026 05 21.
What is China Feihe's biggest competitive threat?
Domestic rival Yili is the named threat, having reportedly overtaken Feihe in retail milk powder share in H1 2025 (18.1% vs Feihe trailing), while H&H Group grew infant formula sales 28.3% year on year and Danone's China nutrition segment grew 13.2% in 2025.
Timeline
  • 2026-03-31Feihe enters Southeast Asia via Philippines with AceKid Activegro formula line
  • 2026-03-26China Feihe reports FY2025 revenue RMB18,112.6M, down 12.7%, and net profit down 42.7%
  • 2026-03-26Morningstar publishes note urging product diversification amid falling birthrate
  • 2025-10-1936kr reports Yili overtook Feihe in H1 2025 overall retail milk powder share, 18.1% vs Feihe trailing
  • 2025-09-01Goldman Sachs downgrades China Feihe to Neutral citing demographic and tariff headwinds
  • 2025-08-28China Feihe reports H1 2025 revenue RMB9,150.5M, down 9.4% year on year
  • 2025-03-28China Feihe reports FY2024 revenue RMB20,748.6M, up 6.2%, boosted by Dragon Year birth uptick
  • 2019-11-13China Feihe IPOs on the Hong Kong Stock Exchange
Revision history
26 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
United Natural FoodsBest BuyMacy's
More in Retail and consumer conglomerates →
Sources